About Pieris Pharmaceuticals
Pieris Pharmaceuticals is a publicly listed company based in Boston (United States) founded in 2001. It operates as a therapeutics are developed using recombinant engineered lipocalin mimics. Pieris Pharmaceuticals has raised $119.22 million across 11 funding rounds from investors including Pfizer, Novo Nordisk and Citadel. The company has 127 employees. Pieris Pharmaceuticals offers products and services including 4-1BB Bispecific Programs. Its focus areas include Diversified Pharmaceuticals. Its legal entity is PIERIS PHARMACEUTICALS, INC.
Company details
Founded in 2001 and based in Boston, United States, Pieris Pharmaceuticals operates in the biotechnology sector. Therapeutics are developed through its proprietary Anticalin platform, which involves engineered lipocalins for transporting small molecules. The platform is being tested in areas such as anemia, asthma, oncology, and infectious diseases including P. aeruginosa. Partnerships are maintained with entities like Daiichi Sankyo, Sanofi, Roche, Zydus Cadila, and Stellis Biopharma.
- Headquarters Boston, United States
- Employees 127
- Stage Public
- SectorsHealthcare
- Website pieris.com
- Social LinkedIn X
- Legal Name Pieris Pharmaceuticals, Inc.
- Annual Revenue$42.81 M (USD)65as on Dec 31, 2023
- Net Profit-$24.54 M (USD)26as on Dec 31, 2023
- EBITDA-$43.47 M (USD)16as on Dec 31, 2022
- Total Equity Funding$119.22M (USD)
in 11 rounds
- Latest Funding Round$17M (USD), Grant
Jun 2021
- InvestorsPfizer
& 17 more
- Employee Count127
Products & Services of Pieris Pharmaceuticals
Pieris Pharmaceuticals offers a comprehensive portfolio of products and services, including 4-1BB Bispecific Programs.
Develops bispecific antibodies for cancer and disease treatment
Funding Insights of Pieris Pharmaceuticals
Pieris Pharmaceuticals has successfully raised a total of $119.22M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $17 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $119.22M
- Total Rounds 11
- Last Round Grant — $17M
- First Round $11.8M
(Oct 2002)
- Investors Count 18
Latest 10 of 11 funding rounds of Pieris Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $17M | Grant | – | – | |
| May 2021 | $20M | Post-IPO | – | – | |
| Mar 2021 | $13M | Post-IPO | – | – | |
| Nov 2019 | $32M | Post-IPO | – | – | |
| Jun 2016 | $16.5M | Post-IPO | – | – | – |
| Dec 2014 | $13.56M | Series C | – | – | |
| Dec 2014 | $40M | Series C | – | – | – |
| Nov 2014 | $8.27M | Series B | – | – | |
| Mar 2008 | $39.2M | Series B | – | – | |
| Nov 2006 | $6.39M | Series B | – | – |
18 investors in total: 18 institutional.
Investors in Pieris Pharmaceuticals
Pieris Pharmaceuticals has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novo Nordisk and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
- | – | aquilocapitalmanagement.com | - | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Early & late stage life sciences focused VC firm funding companies in the US and Europe | – | global-life-science-ventures.com | Munich, Germany | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Buyouts are targeted by this private equity firm in investments. | – | aaccapital.com | Amsterdam, Netherlands | |
- | – | baytechventurecapital.de | - | |
Private equity and accelerator investments are directed toward multiple sectors. | – | riveancapital.com | Brussels, Belgium |
Investor details for Pieris Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pieris Pharmaceuticals
26 people are tracked at Pieris Pharmaceuticals (6 in leadership, 20 in board & advisors); the tracked headcount is 127.
| Name | Role | Group |
|---|---|---|
Mary Fitzgerald | VP, Project Leader PRS-060/AZD1402 | Leadership |
Frank Vollmering | VP, Human Resources | Leadership |
Stephen S. Yoder | President & CEO | Leadership |
Tom Bures | SVP & CFO | Leadership |
Shane Olwill | SVP & Chief Development Officer | Leadership |
Florian Witte | VP & Head of Alliance Management and Early-Stage Project Leadership | Leadership |
James Geraghty | Chairman | Board & advisors |
Michael Richman | Board Member | Board & advisors |
Christopher Kiritsy | Board Member | Board & advisors |
Ann Barbier | Board Member | Board & advisors |
Peter Kiener | Board Member | Board & advisors |
Maya R. Said | Board Member | Board & advisors |
Padmanee Sharma | Board Member | Board & advisors |
Vijay Kuchroo | Board Member | Board & advisors |
Matthew L. Sherman | Board Member | Board & advisors |
Michael Curran | Board Member | Board & advisors |
Dario Vignali | Board Member | Board & advisors |
Ian Adcock | Board Member | Board & advisors |
Bruce Levy | Board Member | Board & advisors |
E. John Werry | Board Member | Board & advisors |
6 more people are available in the full profile.
Complete people profiles for Pieris Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pieris Pharmaceuticals
4 dated milestones of Pieris Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Pieris Pharmaceuticals is founded.
- Funding First funding round of $11.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $17.0M.
Web traffic of Pieris Pharmaceuticals
Websites that share an audience with Pieris Pharmaceuticals (pieris.com).
Websites whose visitors overlap most with Pieris Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| servier.us | 100% | – | #2,050,491 | View details | |
| ensoma.com | 100% | 2.8K | #4,644,561 | View details | |
| paratekpharma.com | 98% | 4K | #5,533,702 | View details | |
| praxismedicines.com | 98% | 35.6K | #1,244,570 | View details | |
| cellarity.com | 96% | 5.8K | #2,884,812 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Pieris Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Pieris Pharmaceuticals (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pieris Pharmaceuticals
Complete news archive for Pieris Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pieris Pharmaceuticals
Pieris Pharmaceuticals was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Pieris Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Pieris Pharmaceuticals is a funded company, having raised a total of $119.22M across 11 funding rounds to date. The company's 1st funding round was a Series B of $6.39M, raised on Oct 2002.
Pieris Pharmaceuticals has 127 employees.
Annual revenue of Pieris Pharmaceuticals is $42.81M as on Dec 31, 2023.
Founded in 2001 and based in Boston, United States, Pieris Pharmaceuticals operates in the biotechnology sector. Therapeutics are developed through its proprietary Anticalin platform, which involves engineered lipocalins for transporting small molecules. The platform is being tested in areas such as anemia, asthma, oncology, and infectious diseases including P. aeruginosa. Partnerships are maintained with entities like Daiichi Sankyo, Sanofi, Roche, Zydus Cadila, and Stellis Biopharma.
Pieris Pharmaceuticals offers 4-1BB Bispecific Programs.
Pieris Pharmaceuticals has 18 investors. Key investors include Pfizer, Novo Nordisk, Citadel, Genentech, and Orbimed.
Pieris Pharmaceuticals operates through Pieris Pharmaceuticals, Inc..